<DOC>
	<DOC>NCT01791140</DOC>
	<brief_summary>This observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy in elderly patients (&gt;/= 65 years of age) with newly diagnosed metastatic colorectal cancer. Patients will be followed until disease progression, death, withdrawal of consent, discontinuation of physician-patient relationship or study closure, whichever comes first.</brief_summary>
	<brief_title>BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 65 years of age Patients with newly diagnosed metastatic colorectal cancer starting firstline treatment with Avastin in combination with fluoropyrimidinebased chemotherapy according to the approved Hungarian Summary of Product Characteristics Patients suitable for Avastin treatment as assessed by the treating physician Any contraindications to Avastin treatment according to the Hungarian Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>